Table 3.
Treatment compliance to MDT recommendation.
| MDT recommendation | No. | Actual received regimens No. (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| PH | TCH | AC-TH | Other | Only Chemo | Only Tras | No treatment | ||
| PH | 41 | 27 (65.9) | 1 (2.4) | 13 (31.7) | ||||
| TCH | 62 | 48 (77.4) | 1 (1.6) | 6 (9.7) | 1 (1.6) | 6 (9.7) | ||
| AC-TH | 119 | 2 (1.7) | 101 (84.9) | 12 (10.1) | 4 (3.4) | |||
Abbreviation: MDT: multidisciplinary treatment; Chemo: chemotherapy; PH: paclitaxel plus trastuzumab; TCH: docetaxel plus carboplatin and trastuzumab; AC-TH: anthracyclines plus cyclophosphamide followed by taxanes and trastuzumab; Other regimen included one patient in TCH group received vinorelbine plus trastuzumab (NH) due to allergic to taxanes; Tras: trastuzumab.